<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03643133</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0150/1704</org_study_id>
    <secondary_id>2017-001165-24</secondary_id>
    <nct_id>NCT03643133</nct_id>
  </id_info>
  <brief_title>Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients</brief_title>
  <acronym>SARCOME13</acronym>
  <official_title>Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial evaluating the impact on efficacy of mifamurtide as add-on treatment to post-operative
      chemotherapy compared to post-operative chemotherapy alone in first-line treatment of
      patients with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or
      localised osteosarcoma with poor histological response).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentre, randomised, open-label, phase II trial, with 2 parallel groups. After
      pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if
      applicable), patients presenting high-risk osteosarcoma (defined as metastatic osteosarcoma
      at diagnosis or localised osteosarcoma with poor histological response) will be randomised
      between 2 arms:

        -  Control arm: post-operative chemotherapy alone (with regimens adapted to the age of
           patient)

        -  Experimental arm : post-operative chemotherapy combined with mifamurtide

      This randomised trial is part of a study recruiting all patients ≤50 years old with a newly
      diagnosed high-grade osteosarcoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 23, 2018</start_date>
  <completion_date type="Anticipated">October 2028</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare event-free survival in the treatment arms</measure>
    <time_frame>Expected average duration of 3 years from randomization</time_frame>
    <description>Event-free survival defined as the time duration from randomisation to time of first event (loco-regional or distant relapse or progression, second malignancy, death from any cause)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare overall survival in the treatment arms</measure>
    <time_frame>Up to 10 years from randomization</time_frame>
    <description>Overall survival defined as the time duration from randomisation to death, whatever the cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare actual and planned cumulative dose and dose intensity of mifamurtide</measure>
    <time_frame>Up to 36 weeks from randomization (until end of treatment)</time_frame>
    <description>Calculation of actual cumulative dose and dose intensity compared to the planned treatment administration schedule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the incidence of adverse events in the treatment arms</measure>
    <time_frame>Up to 40 weeks from randomization (4 weeks after end of treatment)</time_frame>
    <description>Evaluation of toxicity (graded by NCI-CTCAE v4)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Post-operative chemotherapy alone (EI or M-API regimen depending on patient age) :
M-API regimen (≤25 years) :
Doxorubicin 60 mg/m², Day 1 Ifosfamide 3 g/m² Day 1 and 2 Cisplatin 100 mg/m², Day 2
EI regimen (26-50 years) :
Etoposide 75 mg/m²/d, Day 1-4 Ifosfamide 3 g/m²/d, Day 1-4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-operative chemotherapy (EI or M-API regimen) combined with Mifamurtide 2 mg/m² twice weekly post-randomisation for 12 weeks then weekly for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifamurtide</intervention_name>
    <description>48 doses overall over 36 weeks</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>MEPACT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>EI or M-API regimen depending on patient age</intervention_name>
    <description>M-API regimen:
One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days
EI regimen :
5 course of EI, every 21 days</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Registration Criteria:

          1. All newly diagnosed, biopsy-proven, high-grade osteosarcoma, whatever the initial
             extension of the disease

          2. Age &gt;2 years and ≤50 years;

          3. Normal haematological, renal, cardiac and hepatic functions

          4. Planned neoadjuvant chemotherapy as follows:

               1. Methotrexate-Etoposide-Ifosfamide (M-EI regimen) for patients ≤25 years

               2. Doxorubicin-Cisplatin-Ifosfamide (API-AI regimen) for patients 26-50 years

          5. Written informed consent from patients and/or their parents/guardians before enrolment
             and any study-related procedure

          6. Affiliation to a social insurance regimen

        Inclusion Criteria:

          1. Patient with a histologically proven, confirmed by experts pathologists panel (before
             surgery at the latest), high-grade osteosarcoma

          2. Registered at diagnosis into the study

          3. Primary tumour resected after pre-operative chemotherapy

          4. Osteosarcoma classified as high risk because of at least one risk factor:

               1. presence of distant metastases or skip metastases at diagnosis

               2. and/or poor histological response to pre-operative chemotherapy (&gt;10% residual
                  viable cells on the analysis of the primary tumour surgical specimen)

          5. Pre-operative chemotherapy combining

               1. Methotrexate-Etoposide-Ifosfamide (M-EI regimen) for patients ≤25 years

               2. Doxorubicin-Cisplatin-Ifosfamide (API-AI regimen) for patients 26-50 years

          6. Screening laboratory values must meet the following criteria (using CTCAE v4) and
             should be obtained within 7 days prior to randomisation:

               1. Absolute neutrophil count ≥1.0 x 10⁹/L

               2. Platelets ≥100 x 10⁹/L

               3. Haemoglobin ≥8.0 g/mL

               4. Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤2.5 x upper
                  limit of normal (ULN) in the absence of liver metastases or ≤5 x ULN in the
                  presence of liver metastases

               5. Total Bilirubin ≤2 x ULN (except Gilbert Syndrome: &lt;3.0 mg/dL) or Total Bilirubin
                  ≤5.0 x ULN in the presence of liver metastases

               6. Creatinine clearance ≥60 mL/min/1.73 m² according to the Schwartz or Cockcroft
                  formula according to patient's age

          7. Women of childbearing potential must have a negative serum or urine pregnancy test
             (minimum sensitivity 25 IU/L or equivalent units of HCG) done within 7 days prior to
             randomisation

          8. Provision of dated and signed written informed consent for the randomised trial prior
             to any study specific procedures, sampling and analyses.

          9. Patient fit to undergo protocol treatment and follow-up

         10. Affiliation to a social insurance regimen

        Exclusion Criteria:

          1. Low grade osteosarcoma, parosteal or periosteal osteosarcoma

          2. Prior history of other malignancies other than study disease (except for basal cell or
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the
             patient has been free of the disease for at least 3 years.

          3. Osteosarcoma with multiple metastases for whom complete removal is not expected to be
             feasible even after shrinkage with chemotherapy

          4. Progressive disease at any site under initial chemotherapy, confirmed before
             randomisation time, and not totally resected during surgery

          5. Any medical condition precluding treatment with protocol chemotherapy

          6. Fractional Shortening &lt;28% or left ventricular ejection fraction (LVEF) 50% before
             treatment (only for API post-operative chemotherapy) by echocardiogram or multigated
             acquisition (MUGA) scan

          7. Pregnancy or breast-feeding

          8. Hypersensitivity to the active substance or to any of the excipients

          9. Concurrent use of immunodepressive treatment such as cyclosporine, tacrolimus or other
             calcineurin inhibitors

         10. Concurrent use with high-dose non-steroidal anti-inflammatory drugs (NSAIDs,
             cyclooxygenase inhibitors)

         11. Inflammatory or auto-immune disease, allergy or asthma requiring a chronic use of
             steroid treatment that cannot be stopped.

         12. Patients with positive test for human immunodeficiency virus (HIV) or known acquired
             immunodeficiency syndrome (AIDS).

         13. Patients with positive tests for hepatitis B virus surface antigen (HBV sAg) or
             hepatitis C virus ribonucleic acid (HCV RNA) indicating active or chronic infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie MD GASPAR, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy Cancer Campus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie MD PIPERNO-NEUMANN, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laure MONARD</last_name>
    <phone>33 (0)173797309</phone>
    <email>l-monard@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens-Picardie - Service d'oncologie hématologie pédiatrique</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr GOURMEL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers - Service d'oncologie pédiatrique</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr PROUST</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié - Service d'oncologie médicale</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pr ITALIANO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Caen - Service d'oncologie hématologie pédiatrique</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr DEPARIS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Service d'oncologie hématologie pédiatrique</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr PLANTAZ</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret - Unité d'onco-pédiatrie</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr LERVAT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard - IHOPE</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr MAREC-BERARD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard - Service d'oncologie médicale</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pr BLAY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone - service d'oncologie médicale</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pr DUFFAUD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Timone - Service d'oncologie pédiatrique</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr GENTET</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve - Onco-hématologie pédiatrique</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr HAOUY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut régional du Cancer de Montpellier - Service d'oncologie médicale</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr CUPISSOL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Service d'oncologie hématologie pédiatrique</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr CLEIREC</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Service d'oncologie hématologie pédiatrique</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr BENABIDA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Service d'oncologie médicale</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr PIPERNO-NEUMANN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau - Service d'hématologie et d'oncologie pédiatrique</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr TABONE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr BOUDOU-ROUQUETTE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Service d'oncologie pédiatrique</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr PACQUEMENT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis - Service d'oncologie médicale</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr PERRIN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle - Hémato-Immuno-Oncologie Pédiatrique</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pr SCHNEIDER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest (Site René Gauducheau) - Service d'oncologie médicale</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr BOMPAS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre - Onco-hématologie adulte</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pr KURTZ</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Hautepierre - Onco-hématologie pédiatrique</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pr ENTZ-WERLE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Hôpital des Enfants - Service d'Hémato-Immuno-Oncologie</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr CASTEX</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud - service d'oncologie médicale</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr CHEVREAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau - Service d'oncologie médicale</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr NARCISSO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Clocheville - Hématologie et oncologie pédiatrique</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr SERRE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy - Onco-hématologie pédiatrique</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr MANSUY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine - Service d'oncologie médicale</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr RIOS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy - Service de cancérologie de l'enfant et de l'adolescent</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr GASPAR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy - Service d'oncologie médicale</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr DUMONT</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>August 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>October 14, 2019</last_update_submitted>
  <last_update_submitted_qc>October 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone</keyword>
  <keyword>Neoplasm, bone tissue</keyword>
  <keyword>Acetylmuramyl-Alanyl-Isoglutamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifamurtide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared at an individual level, they will be part of the study database including all enrolled patients.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

